Cargando…
A Case of Pembrolizumab-Induced Diabetic Ketoacidosis and Hyperthyroidism in a Patient With Recurrent Esophageal Adenocarcinoma
Immune checkpoint inhibitors (ICI) such as program cell death protein 1 (PD-1) inhibitors are widely used for the treatment of patients with recurrent, locally advanced or metastatic, gastric or gastroesophageal (GE) junction adenocarcinoma. Immune-related adverse events (irAE) such as endocrinopath...
Autores principales: | Salangsang, Jonathan, Sapkota, Surendra, Kharel, Sanjeev, Gupta, Prakash, Kalla, Abhishek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943615/ https://www.ncbi.nlm.nih.gov/pubmed/36825072 http://dx.doi.org/10.7759/cureus.35276 |
Ejemplares similares
-
Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case
por: Sankar, Keerthana, et al.
Publicado: (2021) -
Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy
por: Hernandez, Andrea, et al.
Publicado: (2021) -
Recurrent Concurrent Diabetic Ketoacidosis and Thyroid Storm
por: Crudo, David F, et al.
Publicado: (2021) -
Severe Trichotillomania: An Unusual Trigger of Recurrent Diabetic Ketoacidosis
por: Check, Larissa, et al.
Publicado: (2022) -
COVID-19 Related Predisposition to Diabetic Ketoacidosis
por: Santharaman, Aadhithyaraman, et al.
Publicado: (2023)